European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years

by Marie Weil
January 12, 2021
A A
Share on LinkedinShare on Twitter
  • The European Commission (EC) has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above
  • The EC has also approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above
  • Xofluza, with its rapid reduction in viral replication, could help patients recover more quickly, while also reducing the societal burden of influenza

Basel, 11 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus. The Commission’s Decision follows the positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use in November, 2020, and is based on the results of the phase III CAPSTONE-1, CAPSTONE-2 and BLOCKSTONE studies.1,2,3 This marks the first innovation in mechanism of action for an influenza antiviral approved by the EC in almost 20 years.4

“We are delighted that the European Commission has approved Xofluza, a first-in-class, single-dose oral medicine, for the treatment of influenza,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Xofluza offers patients the first novel mechanism of action for treating influenza approved in Europe in almost 20 years. With approval for both treatment and post-exposure prophylaxis, we are hopeful Xofluza will help patients recover more quickly while also reducing the societal burden of influenza, especially amid the COVID-19 pandemic.”

Influenza is one of the most common, yet serious, infectious diseases, representing a significant threat to public health.5,6 Globally, seasonal influenza epidemics result in three to five million cases of severe disease, millions of hospitalisations and up to 650,000 deaths every year.7,8,9 The WHO estimates that up to 72,000 people in the Europe region die prematurely due to causes associated with influenza each year.10 Antivirals are the only effective treatment specifically designed to target and treat the influenza virus, and their use shows a significant and sustained reduction in the use of key healthcare resources, providing a relief on healthcare costs.11,12,13,14,15

Tags: < Market

Related Industries

Health

Interview with Mr. Sébastien Huron, CEO, Virbac group

March 6, 2023
Health

Bayer driving innovation in radiology with new research across the portfolio presented at ECR

February 23, 2023
Health

Philips recognized as top innovator for 10th consecutive year

February 17, 2023
Health

Bayer completes acquisition of Blackford Analysis Ltd.

February 14, 2023
Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023
Health

Aleksandra Rizo Appointed as CEO of Vividion Therapeutics

January 25, 2023

TÜV SÜD APPOINTS GERALD BACHLER AS NEW CEO OF THE CENTRAL & EASTERN EUROPE (CEE) REGION

March 2, 2023

...

Volkswagen Appoints Nicole Mommsen as Head of Global Communications and Sustainability at Group Technology

March 1, 2023

...

Xiaomi Begins Product Carbon Footprint Assessment and Champions Sustainable Living Awareness

February 27, 2023

...

Schneider Electric investing €40 million in new smart factory in Hungary

March 23, 2023

...

Amazon named as a “Top Employer 2023” in Europe

March 1, 2023

...

EY and IBM Collaborate to Address Complex ESG Challenges and Drive Value-Led Sustainability

March 9, 2023

...

Carlsberg Group appoints new Chief Executive Officer

March 17, 2023

...

CHANGES IN HOLCIM’S BOARD OF DIRECTORS LEADERSHIP

February 25, 2023

...

Danish Carlsberg brewery saves 1 billion litres of water with new technology

March 23, 2023

...

OPPO Pledges Carbon Neutrality Across its Operations by 2050 at MWC 2023

March 2, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist